

## Investor Information

### Exentis Pharma production system of the latest generation delivered

- ◆ Production capacity of up to 10 million tablets per year
- ◆ Freely adjustable release profile of active pharmaceutical ingredients in the human body thanks to tablet geometry
- ◆ Exentis as technology pioneer in the production of 3D-printed tablets

**Stetten, Switzerland, March 22, 2024** – Exentis Group AG, provider of the only 3D technology platform worldwide that enables industrial large-scale manufacturing, delivered an Exentis Pharma production system of the latest generation to a leading manufacturer of pharmaceuticals (CDMO) in Italy.



Exentis Pharma production system of the latest generation being installed in the newly equipped clean room 3D production space of an Italian customer.

The proprietary Exentis 3D technology platform makes it possible for the first time to additively produce tablets with a freely adjustable release profile of active pharmaceutical ingredients in the human body. Thus, Exentis technology creates a completely new market segment.



Modular Exentis Pharma production system for large-scale manufacturing of tablets with a freely adjustable release profile of active pharmaceutical ingredients in the human body, with up to three active ingredients on one tablet. Annual production capacity of up to 200 million tablets per system.

Dr Gereon Heinemann, Chief Executive Officer of Exentis Group AG: “With the delivery of one of our Exentis Pharma production systems of the latest generation to Italy, our innovative clean room production technology is now also present on this market. The delivered 3D system is capable of additively producing up to 10 million tablets per year. Our modularly expandable production systems have an annual production capacity of currently up to 200 million tablets, with up to three active pharmaceutical ingredients per tablet, and with convincing benefits for patients. This makes Exentis a global pioneer in technology platforms for the production of 3D-printed pharmaceutical products.”

In addition to the pharma market, Exentis will use its innovative production technology to tap into further attractive growth markets in the future in which products are also manufactured using clean room technology. These include markets such as pet medicine and nutritional supplements.

## **About Exentis**

As a solution provider, Exentis has the only proprietary 3D technology platform worldwide that allows for industrial large-scale production. Industrialized Additive Manufacturing is universally applicable. For industrial or clean room applications. With free choice of materials, such as metals, ceramics, polymers, pharmaceutical or bio-printing products. The highly flexible 3D production technology combines rework-free component geometries with advantageous cost-benefit ratios. The cold printing process in use is sustainable and conserves materials as well as resources. Our customers, the Exentis 3D community members, can choose between exclusive in-house manufacturing under license agreements or having Exentis produce millions of applications for them as a contract manufacturer.

**For further information please contact:**

**Benjamin del Fabro**

Head of Investor Relations

+41 44 520 46 00

b.delfabro@exentis-group.com

**Visit us also on our website at [www.exentis-group.com](http://www.exentis-group.com).**